UniQure starts $150 mln equity offering following FDA U-turn
BUZZ-UniQure starts $150 mln equity offering following FDA U-turn ** UniQure NV QURE.O looks to raise equity just days after U.S. FDA reversed its earlier position on the Dutch drugmaker's Huntington's disease treatment
** QURE kicks off $150 mln offering of stock and pre-funded warrants
** Co's U.S.-listed shares surged ~78% to close at $48.16 on Weds after U.S. health regulator said it will accept existing trial data for an accelerated review of AMT-130
** Leerink Partners and Stifel joint bookrunners for the equity offering
** U.S.-listed QURE shares finished down 4.1% at $44.39 on Mon. In extended trading, they are up 1.9% to $45.22
** QURE has ~63.1 mln shares outstanding for $2.8 bln current market cap
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal